[S-8 POS] Verona Pharma plc SEC Filing

Rhea-AI Filing Summary

Verona Pharma plc filed an S-8 post-effective amendment registering additional ordinary shares for employee equity plans. The filing lists earlier registration statements and shows successive increases to the pool of shares available under the Verona Pharma plc 2017 Incentive Award Plan and its Second Amended and Restated 2017 Incentive Award Plan, including registrations of 214,000, 2,590,000, 14,333,000, 11,998,660, 65,102,504, 17,132,312, 24,000,000, 34,745,648, and 28,127,576 Ordinary Shares across multiple prior filings. The document is signed by Benjamin Lucas as Principal Executive Officer and Director and by Ebru Can Temucin.

Positive

• Multiple S-8 registrations maintain equity plan capacity with explicit share counts
• Administrative compliance confirmed by signatures from the Principal Executive Officer and a second signer

Negative

• Potential dilution exists as the filing lists large additional share authorizations (e.g., 65,102,504 and 34,745,648)
• No timing or grant details are provided, so investor impact depends on future awards that are not yet disclosed

Insights

Compensation and Equity Plan Analyst

TL;DR: The filing documents expanded employee share pools via multiple prior S-8 registrations.

The filing enumerates several prior registration statements that together authorized additional Ordinary Shares for equity awards under the 2017 Incentive Award Plan and related schemes. This is a standard administrative step to maintain available equity for grants to employees and directors.

Risk drivers include dilution to existing shareholders as new awards are issued and the pace at which the company grants shares; monitor future grant notices or Form 4 filings for concrete dilution timing within the next 12 months.

Corporate Secretary / Governance Specialist

TL;DR: Signatures confirm corporate authorization and routine SEC housekeeping for stock plan registrations.

The listed Registration Nos. trace prior S-8 filings that increased the registered share counts across multiple years, reflecting governance processes to replenish equity plan capacity. The presence of principal officer signatures completes the SEC filing formalities required for those registrations to remain effective.

Dependencies include administrative follow-ups such as plan notices or amendments and any required disclosure of material grants; expect related disclosures via filings (e.g., Form 4) when awards are actually issued.

As filed with the Securities and Exchange Commission on October 7, 2025

Registration No. 333-217521

Registration No. 333-237926

Registration No. 333-248199

Registration No. 333-268389

Registration No. 333-271764

Registration No. 333-279298

Registration No. 333-285347

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-217521

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-237926

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-248199

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-268389

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-271764

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-279298

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-285347

UNDER

THE SECURITIES ACT OF 1933

Verona Pharma plc

(Exact name of registrant as specified in its charter)

United Kingdom		98-1489389
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

3 More London Riverside

London SE1 2RE

United Kingdom

+44 203 283 4200

(Address of Principal Executive Offices) (Zip Code)

VERONA PHARMA PLC UNAPPROVED SHARE OPTION SCHEME

VERONA PHARMA PLC EMI OPTION SCHEME

VERONA PHARMA PLC 2017 INCENTIVE AWARD PLAN

VERONA PHARMA PLC SECOND AMENDED AND RESTATED 2017 INCENTIVE AWARD PLAN

(Full titles of the plans)

Cogency Global Inc.

122 East 42nd Street, 18^th Floor

New York, New York 10168

(800) 221-0102

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Peter N. Handrinos Latham & Watkins LLP 200 Clarendon Street Boston, Massachusetts 02116 (617) 948-6000 James Inness Latham & Watkins LLP 99 Bishopsgate London EC2M 3XF United Kingdom +44 20 7710-1000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer		x		Accelerated filer		¨
Non-accelerated filer		¨		Smaller reporting company		¨
				Emerging growth company		¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

DEREGISTRATION OF SECURITIES

These post-effective amendments (the “Post-Effective Amendments”), filed by Verona Pharma plc, a public limited company incorporated under the laws of England and Wales (the “Company”), remove from registration all ordinary shares, nominal value £0.05 per share, of the Company (the “Ordinary Shares”) previously registered under the following Registration Statements on Form S-8 filed by the Company (the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “SEC”) pertaining to the registration of the Ordinary Shares:

· Registration No. 333-217521, which was previously filed with the SEC on April 28, 2017, registering 214,000 Ordinary Shares under the Verona Pharma plc EMI Option Scheme, 2,590,000 Ordinary Shares under the Verona Pharma plc Unapproved Share Option Scheme and 14,333,000 Ordinary Shares under the Verona Pharma plc 2017 Incentive Award Plan;

· Registration No. 333-237926, which was previously filed with the SEC on April 30, 2020, registering an additional 11,998,660 Ordinary Shares under the Verona Pharma plc 2017 Incentive Award Plan;

· Registration No. 333-248199, which was previously filed with the SEC on August 20, 2020, registering an additional 65,102,504 Ordinary Shares under the Verona Pharma plc 2017 Incentive Award Plan;

· Registration No. 333-268389, which was previously filed with the SEC on November 15, 2022, registering an additional 17,132,312 Ordinary Shares under the Verona Pharma plc 2017 Incentive Award Plan;

· Registration No. 333-271764, which was previously filed with the SEC on May 9, 2023, registering an additional 24,000,000 Ordinary Shares under the Verona Pharma plc Second Amended and Restated 2017 Incentive Award Plan;

· Registration No. 333-279298, which was previously filed with the SEC on May 10, 2024, registering an additional 34,745,648 Ordinary Shares under the Verona Pharma plc Second Amended and Restated 2017 Incentive Award Plan; and

· Registration No. 333-285347, which was previously filed with the SEC on February 27, 2025, registering an additional 28,127,576 Ordinary Shares under the Verona Pharma plc Second Amended and Restated 2017 Incentive Award Plan.

On July 8, 2025, the Company entered into a transaction agreement (the “Transaction Agreement”) with Merck Sharp & Dohme LLC, a New Jersey limited liability company (“Parent”) and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent (“Bidco”), pursuant to which Bidco agreed to acquire the entire issued and to be issued share capital of the Company (the “Transaction”) by means of a court-sanctioned English law scheme of arrangement (the “Scheme of Arrangement”) under Part 26 of the Companies Act 2006. On October 6, 2025, the High Court of Justice of England and Wales (the “Court”) sanctioned the Scheme of Arrangement at a public hearing convened by the Court and the Company. On October 7, 2025, Merck and Bidco consummated the Transaction in accordance with the Transaction Agreement and the Scheme of Arrangement.

As a result of the Transaction, the Company has terminated all offerings of the Company’s securities registered pursuant to its existing registration statements under the Securities Act of 1933, as amended, including the Registration Statements. The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all plan interests and any and all securities registered for issuance under the Registration Statements that remain unsold as of the date hereof. This filing is made in accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that had been registered for issuance that remain unsold at the termination of the relevant offering.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of London, United Kingdom on October 7, 2025.

	VERONA PHARMA PLC
	By:	/s/ Benjamin Lucas
		Name: Benjamin Lucas
		Title: Principal Executive Officer and Director

Pursuant to the requirements of the Securities Act of 1933, as amended, these Post-Effective Amendments to the Registration Statements have been signed by the following persons in the capacities and on the dates indicated.

Signature		Capacity		Date
/s/ Benjamin Lucas		Principal Executive Officer and Director		October 7, 2025
Benjamin Lucas
/s/ Ebru Can Temucin		Principal Accounting Officer, Principal Financial Officer and Director		October 7, 2025
Ebru Can Temucin

SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE OF REGISTRANT

Pursuant to the requirements of the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Verona Pharma plc, has signed these Post-Effective Amendments to the Registration Statements on Form S-8, in the City of New York, State of New York, on October 7, 2025.

COGENCY GLOBAL INC.

(Authorized Representative in the United States)

By:	/s/ Colleen A. De Vries
	Name:	Colleen A. De Vries
	Title:	Senior Vice President on behalf of Cogency Global Inc.

FAQ

What did Verona Pharma (VRNA) register in this S-8 filing?

Multiple prior S-8 registration numbers were referenced, showing additional Ordinary Shares registered under employee plans, including counts such as 28,127,576 and 34,745,648.

Does this filing mean Verona Pharma has issued new shares?

No. The filing registers shares for issuance under equity plans but does not itself report that awards were granted or shares issued.

Who signed the S-8 post-effective amendment for VRNA?

The document is signed by Benjamin Lucas as Principal Executive Officer and Director and by Ebru Can Temucin.

Will this filing dilute existing shareholders immediately?

Not immediately; dilution occurs only when awards are granted and shares are issued. This filing simply ensures registered capacity for future grants.

Where can investors find when grants are actually made?

Investors should monitor subsequent SEC filings such as Form 4 and proxy disclosures for specific grant dates and amounts.